Lifetime Prevalence of Sleepwalking Almost 30% - Medscape
Posted by admin / Under Nonbenzodiazepine![]() Telegraph.co.uk | Lifetime Prevalence of Sleepwalking Almost 30% Medscape Those taking benzodiazepine and nonbenzodiazepine hypnotics were not significantly more likely to have NW compared with those not taking these sleep aids. This finding is interesting in light of recent news stories linking hypnotic agents with ... Sleepwalking Common in America, Study says |
Published on Friday 18th of May 2012 02:17:15 PM
Read more...
Surge in demand for sleeping pills - Daily Post North Wales
Posted by admin / Under NonbenzodiazepineSurge in demand for sleeping pills Daily Post North Wales They included drugs used in the UK, such as benzodiazepines (including temazepam and diazepam), non-benzodiazepines (including zolpidem, zopiclone and zaleplon), barbiturates and sedative antihistamines. The research, from experts at the Jackson Hole ... |
Published on Friday 18th of May 2012 02:17:15 PM
Read more...
Sleeping pills spending by NHS reaches £50m - The Independent
Posted by admin / Under NonbenzodiazepineSleeping pills spending by NHS reaches £50m The Independent They included drugs used in the UK, such as benzodiazepines (including temazepam and diazepam), non-benzodiazepines (including zolpidem, zopiclone and zaleplon), barbiturates and sedative antihistamines. The research, from experts at the Jackson Hole ... |
Published on Friday 18th of May 2012 02:17:15 PM
Read more...
Matched cohort study cautions about increased risk of mortality with hypnotic use - MediNEWS.Direct!
Posted by admin / Under NonbenzodiazepineMatched cohort study cautions about increased risk of mortality with hypnotic use MediNEWS.Direct! A 2007 review by Ramakrishnan et al (American Academy of Family Physicians) recommended newer-generation nonbenzodiazepines, such as, zaleplon, zolpidem, eszopiclone, and ramelteon, as better first-line therapy for long-term management of chronic ... |
Published on Friday 18th of May 2012 02:17:15 PM
Read more...





